Khalid Mezzi

1.2k total citations · 1 hit paper
26 papers, 788 citations indexed

About

Khalid Mezzi is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Khalid Mezzi has authored 26 papers receiving a total of 788 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 19 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Khalid Mezzi's work include Multiple Myeloma Research and Treatments (23 papers), Protein Degradation and Inhibitors (15 papers) and Cancer Treatment and Pharmacology (6 papers). Khalid Mezzi is often cited by papers focused on Multiple Myeloma Research and Treatments (23 papers), Protein Degradation and Inhibitors (15 papers) and Cancer Treatment and Pharmacology (6 papers). Khalid Mezzi collaborates with scholars based in United States, France and Spain. Khalid Mezzi's co-authors include Emma Scott, Ajai Chari, Nina Shah, Saad Z. Usmani, David S. Siegel, Noopur Raje, Adam D. Cohen, Jessica Fowler, Madhav V. Dhodapkar and Phuong K. Morrow and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Khalid Mezzi

26 papers receiving 772 citations

Hit Papers

B-cell maturation antigen (BCMA) in multiple myeloma: rat... 2020 2026 2022 2024 2020 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
    2020 304 citations Nina Shah, Ajai Chari et al. Leukemia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Khalid Mezzi United States 12 499 426 411 142 100 26 788
Sherilyn A. Tuazon United States 10 517 1.0× 494 1.2× 476 1.2× 128 0.9× 118 1.2× 27 941
Caitlin Costello United States 17 455 0.9× 519 1.2× 463 1.1× 157 1.1× 140 1.4× 64 910
Thomas G. Martin United States 15 593 1.2× 534 1.3× 446 1.1× 138 1.0× 150 1.5× 79 946
Shebli Atrash United States 13 521 1.0× 454 1.1× 403 1.0× 112 0.8× 73 0.7× 119 752
Larysa Sanchez United States 12 376 0.8× 335 0.8× 253 0.6× 122 0.9× 118 1.2× 65 606
Sophie Derenne France 8 338 0.7× 362 0.8× 418 1.0× 159 1.1× 72 0.7× 11 780
Cristina Gasparetto United States 19 776 1.6× 561 1.3× 656 1.6× 110 0.8× 124 1.2× 93 1.1k
Claudius Rudin United Kingdom 7 500 1.0× 532 1.2× 352 0.9× 65 0.5× 92 0.9× 16 845
R N Sridhara United States 5 311 0.6× 461 1.1× 343 0.8× 109 0.8× 272 2.7× 8 974
Mariko Ishibashi Japan 13 309 0.6× 322 0.8× 297 0.7× 282 2.0× 38 0.4× 36 748

Countries citing papers authored by Khalid Mezzi

Since Specialization
Citations

This map shows the geographic impact of Khalid Mezzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Khalid Mezzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Khalid Mezzi more than expected).

Fields of papers citing papers by Khalid Mezzi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Khalid Mezzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Khalid Mezzi. The network helps show where Khalid Mezzi may publish in the future.

Co-authorship network of co-authors of Khalid Mezzi

This figure shows the co-authorship network connecting the top 25 collaborators of Khalid Mezzi. A scholar is included among the top collaborators of Khalid Mezzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Khalid Mezzi. Khalid Mezzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Jabbour, Elias, Hagop M. Kantarjian, Nicola Goekbuget, et al.. (2024). Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab. Blood Cancer Journal. 14(1). 203–203. 4 indexed citations
3.
Wei, Andrew H., Andrew W. Roberts, Andrew Spencer, et al.. (2020). Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Reviews. 44. 100672–100672. 152 indexed citations
4.
5.
Shah, Nina, Ajai Chari, Emma Scott, Khalid Mezzi, & Saad Z. Usmani. (2020). B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 34(4). 985–1005. 304 indexed citations breakdown →
6.
Façon, Thierry, Rubén Niesvizky, María‐Victoria Mateos, et al.. (2020). Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. Blood Advances. 4(21). 5449–5459. 26 indexed citations
7.
Cohen, Adam D., Noopur Raje, Jessica Fowler, et al.. (2019). How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma. Clinical Cancer Research. 26(7). 1541–1554. 82 indexed citations
8.
Landgren, Ola, Pieter Sonneveld, Andrzej Jakubowiak, et al.. (2019). Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia. 33(9). 2127–2143. 42 indexed citations
9.
Façon, Thierry, Rubén Niesvizky, Katja Weisel, et al.. (2019). Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR.. Journal of Clinical Oncology. 37(15_suppl). 8028–8028. 3 indexed citations
10.
Jakubowiak, Andrzej, Jagoda Jasielec, Cara A. Rosenbaum, et al.. (2019). Efficacy and Safety of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies. Clinical Lymphoma Myeloma & Leukemia. 19(10). e34–e34. 1 indexed citations
11.
Rifkin, Robert M., E. Susan Amirian, Kathleen M. Aguilar, et al.. (2019). A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting. Therapeutic Advances in Hematology. 10. 152108475–152108475. 13 indexed citations
12.
Dimopoulos, Meletios Α., David S. Siegel, Darrell White, et al.. (2018). Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood. 133(2). 147–155. 29 indexed citations
13.
14.
Rustad, Even H, Venkata Yellapantula, Neha Korde, et al.. (2018). Identifying Ultra-High Risk Smoldering Multiple Myeloma. Blood. 132(Supplement 1). 3192–3192. 1 indexed citations
15.
16.
Rifkin, Robert M., E. Susan Amirian, Thomas W. Wilson, et al.. (2017). Carfilzomib Dosing Patterns and Time to Next Treatment Among Adult Patients with Multiple Myeloma Treated in the US Community Oncology Setting. Blood. 130. 3433–3433. 1 indexed citations
17.
18.
Chari, Ajai, et al.. (2016). Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study. BMC Cancer. 16(1). 912–912. 22 indexed citations
19.
Li, Shuling, et al.. (2016). Treatment Sequencing Patterns in Medicare-Enrolled Patients with Multiple Myeloma. Blood. 128(22). 2120–2120. 1 indexed citations
20.
Reece, Donna, Kevin Song, Richard LeBlanc, et al.. (2013). Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma. The Oncologist. 18(5). 611–618. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sherilyn A. Tuazon Breakdown of academic impact, for papers by Caitlin Costello Breakdown of academic impact, for papers by Thomas G. Martin Breakdown of academic impact, for papers by Shebli Atrash Breakdown of academic impact, for papers by Larysa Sanchez Breakdown of academic impact, for papers by Sophie Derenne Breakdown of academic impact, for papers by Cristina Gasparetto Breakdown of academic impact, for papers by Claudius Rudin Breakdown of academic impact, for papers by R N Sridhara Breakdown of academic impact, for papers by Mariko Ishibashi
Rankless by CCL
2026